U.S. Markets open in 42 mins
  • S&P Futures

    3,722.00
    +52.00 (+1.42%)
     
  • Dow Futures

    29,675.00
    +332.00 (+1.13%)
     
  • Nasdaq Futures

    11,506.00
    +189.75 (+1.68%)
     
  • Russell 2000 Futures

    1,688.90
    +26.40 (+1.59%)
     
  • Crude Oil

    77.93
    +1.22 (+1.59%)
     
  • Gold

    1,647.00
    +13.60 (+0.83%)
     
  • Silver

    18.47
    +0.06 (+0.35%)
     
  • EUR/USD

    0.9636
    +0.0024 (+0.2505%)
     
  • 10-Yr Bond

    3.8210
    -0.0570 (-1.47%)
     
  • Vix

    31.01
    +1.09 (+3.64%)
     
  • GBP/USD

    1.0801
    +0.0118 (+1.1017%)
     
  • USD/JPY

    144.5520
    -0.1280 (-0.0885%)
     
  • BTC-USD

    20,304.28
    +1,370.79 (+7.24%)
     
  • CMC Crypto 200

    463.88
    +30.78 (+7.11%)
     
  • FTSE 100

    7,043.39
    +22.44 (+0.32%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Tvardi Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

·1 min read

HOUSTON, September 08, 2022--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 1:30 p.m. ET as well as in one-on-one meetings in New York City on Wednesday, September 14, 2022.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated clinical programs in hepatocellular carcinoma, breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit https://tvarditherapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005964/en/

Contacts

Tvardi Investor Relations
Sara Manning
ir@tvardi.com